XML 79 R18.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

STOCK-BASED COMPENSATION | 3 Months Ended
--- | ---
Jan. 26, 2020
Share-based Payment Arrangement [Abstract] |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION The Company issues stock options, restricted stock units, and restricted shares as part of its stock incentive plans for employees and non-employee directors. During the three months ended January 26, 2020, stock-based compensation expense was $9.3 million, compared to $7.9 million for the three months ended January 27, 2019. The Company recognizes stock-based compensation expense ratably over the shorter of the vesting period or the individual's retirement eligibility date. The fair value of stock-based compensation granted to retirement-eligible individuals is expensed at the time of grant. At January 26, 2020, there was $32.5 million of total unrecognized compensation expense from stock-based compensation arrangements granted under the plans. This compensation is expected to be recognized over a weighted-average period of approximately 2.6 years. During the three months ended January 26, 2020, cash received from stock option exercises was $36.4 million, compared to $16.0 million for the three months ended January 27, 2019. Shares issued for option exercises, restricted stock units, and restricted shares may be either authorized but unissued shares or shares of treasury stock. Stock Options: The Company’s policy is to grant options with the exercise price equal to the market price of the common stock on the date of grant. Options typically vest over four years and expire ten years after the date of the grant. Effective with fiscal 2020 grants, the Company has determined the equity award value for eligible employees will be delivered fifty percent in stock options as described above and fifty percent in time-vested restricted stock units with a three-year cliff vesting. During the third quarter of fiscal 2018, the Company made a one-time grant of 200 stock options to each active, full-time employee and 100 stock options to each active, part-time employee of the Company on April 30, 2018. The options vest in five years and expire ten years after the grant date. A reconciliation of the number of options outstanding and exercisable (in thousands) as of January 26, 2020 is as follows:
| Shares |  | Weighted- Average Exercise Price |  | Weighted- Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Outstanding at October 27, 2019 | 25,994 |  |  | $ | 26.49 |  |  |  |  |
Granted | 1,004 |  |  | 45.54 |  |  |  |  |
Exercised | 3,059 |  |  | 13.87 |  |  |  |  |
Forfeited | 65 |  |  | 36.56 |  |  |  |  |
Outstanding at January 26, 2020 | 23,874 |  |  | 28.88 |  |  | 5.6 |  | $ | 438,098 |
Exercisable at January 26, 2020 | 16,670 |  |  | $ | 24.51 |  |  | 4.3 |  | $ | 378,778 |
The weighted-average grant date fair value of stock options granted and the total intrinsic value of options exercised (in thousands) during the first three months of fiscal years 2020 and 2019 are as follows.
| Three Months Ended
| January 26, 2020 |  | January 27, 2019
Weighted-average Grant Date Fair Value | $ | 7.67 |  |  | $ | 9.48 |
Intrinsic Value of Exercised Options | 97,946 |  |  | 32,241 |
The fair value of each option award is calculated on the date of grant using the Black-Scholes valuation model utilizing the following weighted-average assumptions:
| Three Months Ended
| January 26, 2020 |  | January 27, 2019
Risk-free Interest Rate | 1.7 | % |  | 2.9 | %
Dividend Yield | 2.0 | % |  | 1.9 | %
Stock Price Volatility | 19.0 | % |  | 19.0 | %
Expected Option Life | 8 years |  |  | 8 years |
As part of the annual valuation process, the Company reassesses the appropriateness of the inputs used in the valuation models. The Company establishes the risk-free interest rate using U.S. Treasury yields as of the grant date. The dividend yield is based on the dividend rate approved by the Company’s Board of Directors and the stock price on the grant date. The expected volatility assumption is based primarily on historical volatility. As a reasonableness test, implied volatility from exchange traded options is also examined to validate the volatility range obtained from the historical analysis. The expected life assumption is based on an analysis of past exercise behavior by option holders. In performing the valuations for option grants, the Company has not stratified option holders as exercise behavior has historically been consistent across all employees. Restricted Stock Units: Restricted stock units are valued equal to the market price of the common stock on the date of grant and vest after three years. These awards accumulate dividend equivalents, which are provided as additional units and are subject to the same vesting requirements as the underlying grant. A reconciliation of the restricted stock units (in thousands) as of January 26, 2020 is as follows:
| Shares |  | Weighted- Average Exercise Price |  | Weighted- Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value
Restricted Units at October 27, 2019 | — |  |  | $ | — |  |  |  |  |
Granted | 169 |  |  | 45.54 |  |  |  |  |
Restricted Units at January 26, 2020 | 169 |  |  | $ | 45.54 |  |  | 2.9 |  | $ | 7,980 |
The weighted-average grant date fair value of restricted stock units granted and the total fair value (in thousands) of restricted stock units granted during the first three months of fiscal years 2020 and 2019 are as follows:
| Three Months Ended
| January 26, 2020 |  | January 27, 2019
Weighted-average Grant Date Fair Value | $ | 45.54 |  |  | $ | — |
Fair Value of Restricted Stock Units Granted | 7,695 |  |  | — |
Restricted Shares: Restricted shares awarded to non-employee directors annually on February 1 are subject to a restricted period which expires the date of the Company’s next annual stockholders meeting. Newly elected directors receive a prorated award of restricted shares of the Company's common stock, which expires on the date of the Company's second succeeding annual stockholders meeting. A reconciliation of the restricted shares (in thousands) as of January 26, 2020 is as follows:
| Shares |  | Weighted- Average Grant Date Fair Value
Restricted at October 27, 2019 | 51 |  |  | $ | 42.23 |
Granted | 1 |  |  | 42.76 |
Restricted at January 26, 2020 | 52 |  |  | $ | 42.24 |
The weighted-average grant date fair value of restricted shares granted and the total fair value (in thousands) of restricted shares granted during the first three months of fiscal years 2020 and 2019 are as follows:
| Three Months Ended
| January 26, 2020 |  | January 27, 2019
Weighted-average Grant Date Fair Value | $ | 42.76 |  |  | $ | 34.33 |
Fair Value of Restricted Shares Granted | 53 |  |  | 53 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration